drugset / Trial / NCT01514981

AMG 761 in Adults With Asthma

NCT01514981

Phase 1 Terminated 7 enrolled Amgen
RandomizedSingle-groupTriple-blindBasic science

Summary

The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.

Timeline

Start
2011-12
Primary completion
2014-01
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mogamulizumab Monoclonal antibody

Indications